Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.49 USD | -1.08% | -11.59% | -45.80% |
Financials (USD)
Sales 2024 * | 34.3M | Sales 2025 * | 24.82M | Capitalization | 451M |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -242M | EV / Sales 2024 * | 5.8 x |
Net cash position 2024 * | 252M | Net cash position 2025 * | 95M | EV / Sales 2025 * | 14.4 x |
P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-2.14
x | Employees | 265 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.68% |
Latest transcript on Editas Medicine, Inc.
1 day | -1.08% | ||
1 week | -11.59% | ||
Current month | -26.01% | ||
1 month | -29.16% | ||
3 months | -32.14% | ||
6 months | -14.62% | ||
Current year | -45.80% |
Managers | Title | Age | Since |
---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 22-05-31 |
Erick Lucera
DFI | Director of Finance/CFO | 57 | 23-05-16 |
Linda Burkly
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Emma Reeve
CHM | Chairman | 63 | 21-09-02 |
David Scadden
BRD | Director/Board Member | 71 | 19-02-05 |
Akshay Vaishnaw
BRD | Director/Board Member | 61 | 16-07-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.83% | 2 M€ | -25.75% | ||
0.13% | 2 M€ | -.--% | ||
0.09% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 5.49 | -1.08% | 2,264,535 |
24-04-18 | 5.55 | -1.07% | 1,715,551 |
24-04-17 | 5.61 | -4.10% | 1,910,234 |
24-04-16 | 5.85 | -3.78% | 1,338,818 |
24-04-15 | 6.08 | -2.09% | 1,771,828 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.80% | 451M | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- EDIT Stock